Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira
{"title":"每次皮下注射艾氯胺酮治疗难治性抑郁症后的反应概率","authors":"Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira","doi":"10.1016/j.rpsm.2020.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120301178/pdfft?md5=8b99e6d2b06dcf3a387f454ce0eb0ade&pid=1-s2.0-S1888989120301178-main.pdf","citationCount":"2","resultStr":"{\"title\":\"The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression\",\"authors\":\"Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira\",\"doi\":\"10.1016/j.rpsm.2020.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>\",\"PeriodicalId\":21391,\"journal\":{\"name\":\"Revista de psiquiatria y salud mental\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1888989120301178/pdfft?md5=8b99e6d2b06dcf3a387f454ce0eb0ade&pid=1-s2.0-S1888989120301178-main.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de psiquiatria y salud mental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1888989120301178\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de psiquiatria y salud mental","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1888989120301178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression
Introduction
The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).
Material and methods
We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0 mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24 h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.
Results
The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.
Conclusions
Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.
期刊介绍:
The Spanish Journal of Psychiatry and Mental Health (SJPMH), incorporated into ISSN 1888-9891, is the official scientific publication of the Spanish Society of Psychiatry and Mental Health. The journal focuses on studying mental illnesses, their pathological processes, and their psychosocial consequences, and aims to disseminate scientific advances in all areas related to mental health and illness. SJPMH accepts unpublished works on psychiatry and mental health, including their medical and social implications. The journal provides space for research in the biological, clinical, and psychosocial fields. Manuscripts undergo peer-review by external reviewers before being accepted for publication. SJPMH is indexed in Index Medicus/Medline, IBECS, Social Sciences Citation Index Journal Citation Reports/Social Sciences Edition, and Current Contents/Social and Behavioral Sciences.